Pinals R S
Department of Medicine, UMDNJ-Robert Wood Johnson Medical School, Princeton 08540.
J Rheumatol Suppl. 1988 Sep;16:1-4.
Sulfasalazine was synthesized almost 50 years ago specifically to treat rheumatoid arthritis. At that time bacterial infection was believed to be an important factor in pathogenesis. The linkage of sulfapyridine and salicylate with an azobond was viewed as a method of combining antibacterial and antiinflammatory actions while minimizing gastric irritation. Early therapeutic results were encouraging, but the drug was discarded as an antirheumatic agent for 30 years, until its serendipitous rediscovery. Subsequent controlled trials have confirmed its efficacy, which may be related to sulfasalazine itself or to the sulfapyridine moiety.
柳氮磺胺吡啶大约在50年前被合成，专门用于治疗类风湿性关节炎。当时，细菌感染被认为是发病机制中的一个重要因素。磺胺吡啶和水杨酸盐通过偶氮键连接，被视为一种结合抗菌和抗炎作用同时将胃部刺激降至最低的方法。早期的治疗结果令人鼓舞，但该药物作为抗风湿药物被弃用了30年，直到它被意外重新发现。随后的对照试验证实了其疗效，这可能与柳氮磺胺吡啶本身或磺胺吡啶部分有关。
